Quantifying Morbidity Risk Attributed to Red‐Cell Transfusion Volume in Optimally Transfused Patients With β‐Thalassemia

Documenti analoghi

• Lifetime Risk of Liver Disease in Patients With β‐Thalassemia: Data From the de‐LIGHT Retrospective Cohort Study
  di: Khaled M. Musallam, et al.
  Pubblicazione: (2025)
• The Efficacy of Mitapivat in Case of Transfusion Dependence Linked to Beta Thalassemia Trait Associated with Pyruvate Kinase Deficiency
  di: Carmina Fatigati, et al.
  Pubblicazione: (2024)
• Luspatercept in Transfusion‐Dependent β‐Thalassemia: The Benefit Is Real, and So Are the Risks
  di: Khaled M. Musallam
  Pubblicazione: (2025)
• TIF Guidelines for the Management of Transfusion‐Dependent β‐Thalassemia
  di: Khaled M. Musallam, et al.
  Pubblicazione: (2025)
• Beta‐Thalassemia in Spain: Results From the National Thalassemia Registry and Molecular Analysis of Patients With Transfusion‐Dependent Thalassemia
  di: Ana Villegas, et al.
  Pubblicazione: (2026)